These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12625864)

  • 1. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal selegiline: targeted effects on monoamine oxidases in the brain.
    Wecker L; James S; Copeland N; Pacheco MA
    Biol Psychiatry; 2003 Nov; 54(10):1099-104. PubMed ID: 14625153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus transdermal selegiline: antidepressant-like activity in rats.
    Gordon MN; Muller CD; Sherman KA; Morgan DG; Azzaro AJ; Wecker L
    Pharmacol Biochem Behav; 1999 Jul; 63(3):501-6. PubMed ID: 10418793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
    Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
    Mahmood I
    Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of platelet monoamine oxidase type B by selegiline.
    Heinonen EH; Anttila MI; Nyman LM; Pyykkö KA; Vuorinen JA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):597-601. PubMed ID: 9243352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?
    Mahmood I
    Ther Drug Monit; 1998 Dec; 20(6):717-21. PubMed ID: 9853994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
    Murphy MP; Wu PH; Milgram NW; Ivy GO
    Neurochem Res; 1993 Dec; 18(12):1299-304. PubMed ID: 8272194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.
    Harris DS; Everhart T; Jacob P; Lin E; Mendelson JE; Jones RT
    BMC Clin Pharmacol; 2009 Aug; 9():13. PubMed ID: 19646280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.
    Preskorn SH
    J Psychiatr Pract; 2006 May; 12(3):168-72. PubMed ID: 16732136
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline transdermal system: in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An enzymatic assay for the MAO-B inhibitor selegiline in plasma.
    Mahmood I; Neau SH; Mason WD
    J Pharm Biomed Anal; 1994 Jul; 12(7):895-9. PubMed ID: 7981318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.